Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 23, 2026
Reporting Period: The filing addresses events occurring between February 6, 2026, and February 23, 2026, specifically regarding stock listing compliance.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding the company's stock listing status.
Material Changes
Regulatory Status Change: The Company regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement.
Stock Price Performance: The closing bid price of the Company's common stock was at or above $1.00 per share for 10 consecutive business days (February 6, 2026, through February 20, 2026).
Outcome: The Nasdaq Listing Qualifications Department determined the matter is closed.
Guidance, Outlook, and Risks
Management Commentary: On February 24, 2026, the Company issued a press release (Exhibit 99.1) confirming the receipt of the Notification Letter and the restoration of compliance.
Risks and Contingencies: The filing resolves a prior risk of delisting due to non-compliance with the minimum bid price rule. No new risks or unusual items are disclosed in this specific report.
Investor Verification Checklist
- Verify the current trading price of ADIL on the Nasdaq Capital Market to ensure continued compliance with the $1.00 minimum bid price.
- Review the attached Press Release (Exhibit 99.1) for any additional context regarding the stock price recovery.
- Confirm that no other Nasdaq listing deficiencies exist, as this filing only addresses the minimum bid price requirement.